Enhanced Malaria Vaccine Compositions and Methods

Improved recombinant MVA viral vectors for generating an immune response to malaria, featuring novel adjuvants, immune-modulating proteins, and enhanced vector stability and durability.

The original patent described recombinant MVA viral vectors for malaria immunization, but these vectors had limitations in terms of immunogenicity, safety, and durability. The new inventive concept addresses these limitations by introducing novel adjuvants, immune-modulating proteins, and vector enhancements, resulting in improved vaccine compositions and methods.

The enhanced malaria vaccine compositions and methods comprise recombinant MVA viral vectors with novel adjuvants, such as toll-like receptor agonists, to enhance immunogenicity. Additionally, the vectors may include immune-modulating proteins, such as cytokines, to regulate the immune response. Furthermore, the vectors may be engineered to include proteins that enhance vector stability and durability, ensuring a more sustained immune response. The new claims describe specific formulations and methods for preventing or treating malaria, including boosting and priming regimens.

The new claims introduce novel adjuvants, immune-modulating proteins, and vector enhancements, which are not obvious from the original patent. The combination of these elements provides a significant improvement in immunogenicity, safety, and durability, making the new inventive concept novel and non-obvious.

Alternative embodiments of the inventive concept may include different adjuvants, immune-modulating proteins, or vector enhancements. For example, other toll-like receptor agonists or cytokines could be used, or different insertion sites for the nucleic acid sequences could be explored. Additionally, the recombinant MVA viral vectors could be formulated with other immunogenic polypeptides or used in combination with other vaccine platforms.

The enhanced malaria vaccine compositions and methods have significant commercial potential in the global vaccine market, particularly in regions where malaria is endemic. The improved safety, efficacy, and durability of the vaccine could lead to increased adoption and reduced healthcare costs.